Lucigenin chemiluminescence as a probe for measuring reactive oxygen species production in Escherichia coli

1990 ◽  
Vol 186 (2) ◽  
pp. 316-319 ◽  
Author(s):  
Timothy R. Peters ◽  
Jeffrey M. Tosk ◽  
Eric A. Goulbourne
Keyword(s):  
Escherichia Coli ◽  
Reactive Oxygen Species ◽  
Reactive Oxygen Species Production ◽  
Reactive Oxygen ◽  
Oxygen Species ◽  
Species Production ◽  
Lucigenin Chemiluminescence

scholarly journals Vesicular Formation of Trans-Ferulic Acid: an Efficient Approach to Improve the Radical Scavenging and Antimicrobial Properties

2021 ◽  
Author(s):  
Anahita Rezaeiroshan ◽  
Majid Saeedi ◽  
Katayoun Morteza-Semnani ◽  
Jafar Akbari ◽  
Akbar Hedayatizadeh-Omran ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Reactive Oxygen Species ◽  
Ferulic Acid ◽  
Reactive Oxygen Species Production ◽  
Radical Scavenging ◽  
Reactive Oxygen ◽  
Entrapment Efficiency ◽  
The Body ◽  
Oxygen Species ◽  
Species Production

Abstract Purposes Reactive oxygen species production is harmful to human’s health. The presence of antioxidants in the body may help to diminish reactive oxygen species. Trans-ferulic acid is a good antioxidant, but its low water solubility excludes its utilization. The study aims to explore whether a vesicular drug delivery could be a way to overcome the poor absorption of trans-ferulic acid hence improving its antimicrobial efficiency and antioxidant effect. Methods Niosomal vesicles containing the drug were prepared by film hydration method. The obtained vesicles were investigated in terms of morphology, size, entrapment efficiency, release behavior, cellular cytotoxicity, antioxidant, cellular protection study, and antimicrobial evaluations. Results The optimized niosomal formulation had a particle size of 158.7 nm and entrapment efficiency of 21.64%. The results showed that the optimized formulation containing 25 μM of trans-ferulic acid could enhance the viability of human foreskin fibroblast HFF cell line against reactive oxygen species production. The minimum effective dose of the plain drug and the niosomal formulation against Staphylococcus aurous (ATCC 29213) was 750 µg/mL and 375 µg/mL, respectively, and for Escherichia coli (ATCC 25922), it was 750 µg/mL and 187/5 µg/mL, respectively. The formulation could also improve the minimum bactericidal concentration of the drug in Staphylococcus aurous, Escherichia coli, and Acinobacter baumannii (ATCC 19606). Conclusion These results revealed an improvement in both antibacterial and antioxidant effects of the drug in the niosomal formulation.

Sign in / Sign up

Export Citation Format

Share Document